Penumbra

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Penumbra reports robust Q2 earnings, eyes growth amidst challenges

Penumbra's Q2 2024 earnings call showcased strong financial performance, operational efficiency, and a commitment to innovation and market access initiatives.
While facing challenges in revenue guidance reduction and competitive dynamics, the company's strengths in product performance and growth prospects position it well for the future.
Opportunities exist in leveraging innovation, addressing market challenges, and optimizing margins to drive sustained growth and competitiveness in the industry.

Penumbra reports strong Q3 earnings, eyes global blood clot market

Penumbra's Q3 2024 earnings call showcased robust financial performance, driven by revenue growth and margin expansion. The company's innovative technologies and regulatory milestones position it for future success in the blood clot treatment market. While facing challenges in sustaining growth and navigating market dynamics, Penumbra has opportunities to capitalize on its strengths and drive global transformation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

ALAMEDA, Calif., May 4, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2021.

Penumbra, Inc. Reports First Quarter 2021 Financial Results

iShares U.S. Medical Devices ETF

If you like good news and support from experts, this one's for you.

This Medical Device Company Just Got a Big Boost

ALAMEDA, Calif., April 27, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021.

Penumbra, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference

Growth across vascular thrombectomy and embolization products is expected to have contributed to Penumbra's (PEN) Q1 performance.

Penumbra (PEN) to Report Q1 Earnings: What's in the Cards?

ENDRA Life Sciences

Natus Medical Inc

Owens & Minor

Apollo Medical Hlds

Here are a few MedTech stocks, Natus Medical (NTUS), Owens & Minor (OMI), ENDRA Life Sciences (NDRA), Penumbra (PEN), Apollo Medical (AMEH), which might be prudent investment choices now.

5 MedTech Outperformers With Nearly 40% or More Gain in 2021

ALAMEDA, Calif., April 13, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2021 after market close on Tuesday, May 4, 2021 at 4:30 PM Eastern Time.

Penumbra, Inc. Schedules First Quarter 2021 Earnings Release and Conference Call for May 4, 2021

AbbVie

Adobe

General Motors

KLA-Tencor

Netflix

NIKE

Omnicom Group

Progyny

Constellation Brands

Tesla

Netflix and Facebook are among the top stocks for April. Q.ai's Artificial Intelligence has also dug up top tech stocks, top consumer stocks, top quality value stocks, and top growth stocks.

Top Stocks To Buy This Month Amid Optimistic Markets

Danaos

Top Picks for Investors Interested in the Shipping and Medical Space.

Top Stock Picks for Week of March 29, 2021

Is (PEN) Outperforming Other Medical Stocks This Year?

Has Penumbra (PEN) Outpaced Other Medical Stocks This Year?

Penumbra's (PEN) INDIGO System Lightning 7 assists physicians in easing arterial thrombus removal with single-session results.

Penumbra (PEN) Launches INDIGO System Lightning 7 in US

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #mechanicalthrombectomy--Indigo® System CAT™7 Aspiration Catheter with Lightning™ Intelligent Aspiration powered by Penumbra ENGINE® is now commercially available in the U.S.

Penumbra Announces U.S. Commercial Availability of INDIGO System Lightning 7

New York, New York--(Newsfile Corp. - March 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Penumbra, Inc. ("Penumbra") (NYSE: PEN) between August 3, 2020 and December 15, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get more information go...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Penumbra, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 16, 2021 - PEN

Los Angeles, California--(Newsfile Corp. - March 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Penumbra, Inc. ("Penumbra" or "the Company") (NYSE: PEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between August 3, 2020 and December 15, 2020, inclusive...

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Penumbra, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

Clover Health Investments

iRhythm Technologies

Nutanix

NEW ORLEANS, March 15, 2021 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CLOV, IRTC, NTNX, PEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

New York, New York--(Newsfile Corp. - March 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Penumbra, Inc. (NYSE: PEN) alleging that the Company violated federal securities laws.Class Period: August 3, 2020 and December 15, 2020Lead Plaintiff Deadline: March 16, 2021Learn more about your recoverable losses in PEN:

PEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 16, 2021 in the Class Action Filed on Behalf of Penumbra, Inc. Limited Shareholders

Investors with losses are encouraged to contact the firm before March 16, 2021 ; click  here  to submit trade information ​

Penumbra, Inc. Investors: Last Day to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Los Angeles, California--(Newsfile Corp. - March 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Penumbra, Inc. ("Penumbra" or "the Company") (NYSE: PEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between August 3, 2020 and December 15, 2020, inclusive...

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Penumbra, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

New York, New York--(Newsfile Corp. - March 15, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Penumbra, Inc. (NYSE: PEN) between August 3, 2020 and December 15, 2020, inclusive (the "Class Period"), of the important March 16, 2021 lead plaintiff deadline.SO WHAT: If you purchased Penumbra securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

Final Deadline Tomorrow: Rosen, Trusted National Trial Counsel, Encourages Penumbra, Inc. Investors to Secure Counsel Before Important March 16 Deadline - PEN

Rocky Brands

Sturm, Ruger & Company

Low-beta stocks may be able to help sail through the choppy market conditions.

Buy These 5 Low-Beta Stocks & Combat the Choppy Market

RADNOR, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Penumbra, Inc. (NYSE: PEN) (“Penumbra”) on behalf of those who purchased or acquired Penumbra common stock between August 3, 2020 and December 15, 2020 , inclusive (the “Class Period”).

KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for PENUMBRA, INC. Investors – PEN

New York, New York--(Newsfile Corp. - March 13, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Penumbra, Inc. (NYSE: PEN) between August 3, 2020 and December 15, 2020, inclusive (the "Class Period"), of the important March 16, 2021 lead plaintiff deadline.SO WHAT: If you purchased Penumbra securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

PEN Final Deadline Tuesday: Rosen, A Leading and Top Ranked Law Firm, Encourages Penumbra, Inc. Investors to Secure Counsel Before Important March 16 Deadline - PEN

Radnor, Pennsylvania--(Newsfile Corp. - March 13, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Penumbra, Inc. (NYSE: PEN) ("Penumbra") on behalf of those who purchased or acquired Penumbra common stock between August 3, 2020 and December 15, 2020, inclusive (the "Class Period").Final Deadline Reminder: Investors who purchased or acquired Penumbra common stock during the Class Period...

Final Deadline Approaching on March 16, 2021: Kessler Topaz Meltzer & Check, LLP Reminds Penumbra, Inc. Investors of Class Action Lawsuit Deadline

RADNOR, Pa.--(BUSINESS WIRE)---- $PEN #classaction--Kessler Topaz Meltzer & Check, LLP Announces 4 Day Deadline Reminder in Securities Class Action Lawsuit Filed Against Penumbra, Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Four Days Until Deadline in Securities Fraud Class Action Lawsuit Filed Against Penumbra, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $PEN #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Penumbra, Inc. (PEN)

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Penumbra, Inc. (PEN)

Los Angeles, California--(Newsfile Corp. - March 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Penumbra, Inc. ("Penumbra" or "the Company") (NYSE: PEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between August 3, 2020 and December 15, 2020, inclusive...

TUESDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Penumbra, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

News for Penumbra Stock (PEN)